Table 2.

Amino acid sequences of complementarity-determining region (CDR) sets introduced into human V_H/V_L single-domain antibody (sdAb) scaffolds for biophysical stability assessment.

VL CDR set	CDR-L1a	CDR-L2b	CDR-L3c	CDR-L3 length (aa)
1	RASQSVLVHLA	GDSYRAD	QQTFYPST	8
2	RASQSVISNLA	GDSFRAF	QQVAHPTT	8
3	RASQSVTDTLLA	GISHRAD	QQLVHPFT	8
4	RASQSVVHNLA	GLSTRAH	QQFDHPYT	8
5	RASQSVSSNLA	GASLRAT	QQYLIPPAT	9
6	RASQSVAPSLLA	GTSTRAP	QQPTLFPTT	9
7	RASQSVNLPYLA	GVSTRAY	QQIAVTPYT	9
8	RASQSVDYNLA	DISFRAN	QQSLSPPAT	9
9	RASQSVNITSLA	GTSTRAD	QQTNTHHPVT	10
10	RASQSVSSYLA	GLSLRAV	QQTDSFFPFT	10
11	RASQSVPIVLA	GHSLRAD	QQLAFFDPFT	10
12	RASQSVYLNLA	GVSVRAD	QQILLFYPHT	10
VH CDR set	CDR-H1d	CDR-H2e	CDR-H3f	CDR-H3 length (aa)
1	SNAWMS	RITSKTDGGTTD	DQANAFDI	8
2	DGYAMH	VTNNGGSTS	QSITGPTGAFDI	12
3	SSYAMS	AISGGGDHTY	EGMVRGVSSAPFDY	14
4	ISESMT	AISSSGGSTY	KKIDGARYDY	10
5	NTLSMG	AVSRSGGSTY	AATKSNTTAYRLSFDY	16
6	SMYRMG	VITRNGSSTY	TSGSSYLDAAHVYDY	15
7	SMDPMA	AGSSTGRTTY	APYGANWYRDEYAY	14
8	SRYPVA	VISSTGTSTY	NSQRTRLQDPNEYDY	15
9	SNRNMG	GISWGGGSTR	EFGHNIATSSDEYDY	15
10	NFYAMS	GVSRDGLTTL	VITGVWNKVDVNSRSYHY	18
11	SPTAMG	HITWSRGTTR	STFLRILPEESAYTY	15
12	DNYAMA	TIDWGDGGAR	ARQSRVNLDVARYDY	15

^aIMGT positions 24–40 in the acceptor sdAb were replaced with the indicated sequence.

^bIMGT positions 56–69 in the acceptor sdAb were replaced with the indicated sequence.

^cIMGT positions 105–117 in the acceptor sdAb were replaced with the indicated sequence.

^dIMGT positions 35–40 in the acceptor sdAb were replaced with the indicated sequence.

^eIMGT positions 55–66 in the acceptor sdAb were replaced with the indicated sequence.

^fIMGT positions 105–117 in the acceptor sdAb were replaced with the indicated sequence.